CDCP1 Antibody

What is CDCP1 and why is it a significant target in cancer research?

CDCP1 (CUB-domain-containing protein 1) is a transmembrane glycoprotein that plays a crucial role in cellular signaling, particularly in processes related to cell adhesion and migration. It is primarily located in the plasma membrane, where its three extracellular CUB domains facilitate interactions with other proteins and extracellular matrix components . CDCP1 has gained significant attention in cancer research due to its elevated expression in multiple cancer types, including breast, colon, pancreatic, ovarian, and lung cancers .

The significance of CDCP1 as a cancer target stems from several key characteristics:

• It is highly expressed in metastatic colon and breast tumors but has restricted expression in normal human tissues, making it an ideal candidate for targeted therapies .

• It functions as an important hub of oncogenic signaling, particularly through its interactions with Src family kinases .

• Its phosphorylation at specific tyrosine residues, including Tyr 734, enhances signaling capabilities that impact tumor progression .

• Its expression increases in metastatic lesions compared to primary tumors in some cancer types, suggesting a role in cancer progression and metastasis .

These characteristics make CDCP1 not only a potential biomarker for cancer detection but also a promising therapeutic target for antibody-based treatments, including antibody-drug conjugates (ADCs) .

What detection methods are available for CDCP1 expression in research samples?

Researchers have several validated methods for detecting CDCP1 expression in various sample types:

Protein Detection Methods:

• Western Blotting (WB): Effective for detecting both the 135 kDa full-length CDCP1 (CDCP1-FL) and the 70 kDa C-terminal fragment (CDCP1-CTF) . The choice of antibody is critical, as some (like antibody 4115) target the intracellular carboxyl-terminal region and can detect both forms, while others may be specific to certain domains .

• Immunohistochemistry (IHC): Used extensively for evaluating CDCP1 expression in tumor tissues. In clinical studies, IHC has been employed to assess CDCP1 expression in over 300 samples from six types of cancer .

• Immunofluorescence (IF): Allows visualization of CDCP1 localization within cells and tissues .

• Flow Cytometry: Enables quantification of cell surface CDCP1 levels, which has been shown to correlate with sensitivity to anti-CDCP1 ADCs. Studies have determined that approximately 5×10⁴ anti-CDCP1 antibodies bound per cell represents a threshold for predicting anti-CDCP1 ADC efficacy .

• Enzyme-Linked Immunosorbent Assay (ELISA): Provides quantitative measurement of CDCP1 in solution .

Molecular Detection Methods:

• RT-PCR and qPCR: For quantification of CDCP1 mRNA expression.

• Transcriptomic Analysis: Large-scale analyses have been used to evaluate CDCP1 mRNA expression across 23 types of cancer and normal tissues .

When selecting detection methods, researchers should consider both the sensitivity requirements and the specific form of CDCP1 they wish to detect (full-length vs. cleaved fragment), as these factors will influence the choice of antibody and detection technique.

How does CDCP1 expression vary across different cancer types?

CDCP1 expression shows distinctive patterns across cancer types, with important implications for its potential as a therapeutic target:

Expression in Breast Cancer:

• Present in approximately 70% of triple-negative breast cancers (TNBCs)

• Expressed in 80% of HER2-positive tumors

• In ER+/HER2- tumors, expression increases from 44.9% in primary tumors to 56.4% in lymph node metastases and 74.3% in distant metastases

Expression in Other Cancer Types:

• Analysis of CDCP1 expression across multiple cancer types revealed elevated levels in the majority of cancers examined

• Particularly high expression has been noted in:

  • Ovarian clear cell carcinoma

  • High-grade serous ovarian carcinoma

  • Pancreatic ductal adenocarcinoma (PDAC)

  • Prostate cancer

  • Colorectal cancer

  • Lung cancer

  • Kidney cancer

Expression in Cell Lines:

• Studies have characterized CDCP1 expression in at least 49 cancer cell lines

• PDAC cell lines typically show the highest levels of cell surface CDCP1

• Some cell lines express only full-length CDCP1-FL (e.g., A498, 786-O, A549, HT29)

• Others express a mixture of CDCP1-FL and CDCP1-CTF (e.g., DU145, EBC-1, HCT116)

• Some express only the cleaved fragment CDCP1-CTF (e.g., TKCC05)

The heterogeneity in CDCP1 expression patterns both between and within cancer types suggests that patient selection strategies based on CDCP1 expression levels will be crucial for the successful clinical application of CDCP1-targeted therapies.

What are the current approaches for developing CDCP1-targeted antibody-drug conjugates?

Development of CDCP1-targeted antibody-drug conjugates (ADCs) represents a rapidly advancing area of research with several sophisticated approaches:

Antibody Engineering and Selection:

• Multiple anti-CDCP1 antibodies have been developed and characterized, including mouse monoclonal (10D7), human/mouse chimeric (ch10D7), and fully human antibodies (4A06, IgG-CL03) .

• Chimeric antibody development has been employed to reduce immunogenicity while maintaining binding affinity. For example, ch10D7 was created by engineering murine variable heavy (VH) and light (VL) chains onto a human IgG1κ backbone, resulting in an antibody that maintains the binding kinetics of the parent murine antibody .

• Surface plasmon resonance (SPR) spectroscopy has been used to determine binding kinetics and affinity (KD) of antibodies to recombinant CDCP1 extracellular domain (CDCP1-ECD) .

Payload Selection and Conjugation:

• Monomethyl auristatin E (MMAE), a potent microtubule disruptor, has been successfully conjugated to anti-CDCP1 antibodies including ch10D7 .

• Radioactive isotopes such as 89Zirconium and 177Lutetium have been conjugated to anti-CDCP1 antibodies for imaging and radio-ligand therapy applications, respectively .

Internalization and Trafficking Studies:

• Anti-CDCP1 antibodies (ch10D7 and 10D7) have been shown to induce signaling via Src accompanied by rapid internalization of antibody-CDCP1 complexes in cancer cells .

• Extended exposure to these antibodies results in significant reduction of CDCP1 expression after 24 hours and complete loss after 48 hours, with receptor re-expression occurring within 24-48 hours after antibody withdrawal .

Efficacy Assessment:

• In vitro cytotoxicity assays across multiple cell lines have demonstrated a correlation between CDCP1 expression levels and sensitivity to anti-CDCP1 ADCs, with a threshold of approximately 5×10⁴ anti-CDCP1 antibodies bound per cell suggested as a minimum for predicting efficacy .

• Combination studies with other targeted therapies, such as HER2-targeting ADC T-DM1, have shown enhanced efficacy against CDCP1+/HER2+ tumors compared to either agent alone .

These multifaceted approaches to CDCP1-targeted ADC development highlight the complexity of the field and the important considerations for researchers pursuing this therapeutic strategy.

How can CDCP1 antibodies be utilized for in vivo imaging of tumors?

CDCP1 antibodies have demonstrated significant potential for in vivo imaging of various cancer types, with several approaches showing promise in preclinical models:

Radiolabeling Strategies:

• 89Zirconium (89Zr) Labeling: Multiple studies have successfully conjugated 89Zr to anti-CDCP1 antibodies, including ch10D7 and 4A06, for positron emission tomography-computed tomography (PET-CT) imaging .

• The 89Zr-labeled antibodies have shown strong accumulation in CDCP1-expressing tumors, enabling effective detection of both primary and metastatic lesions .

Preclinical Imaging Applications:

• Detection of Primary Tumors: PET-CT imaging with 89Zr-ch10D7 has been effective for the detection of primary CDCP1-expressing triple-negative breast cancers (TNBCs) in mouse models .

• Metastasis Detection: The same imaging approach has successfully visualized metastatic TNBC lesions in preclinical models .

• Pancreatic Cancer Imaging: 89Zr-labeled antibody IgG-CL03, directed against the CDCP1-ATF region proximal to protease cleavage sites at 368Arg and 369Lys, demonstrated strong accumulation in subcutaneous xenografts of PDAC PL5 cells in mice .

• Prostate Cancer Visualization: Antibody A406 effectively delivered 89Zr for detection of CDCP1-expressing prostate cancer xenografts .

Methodological Considerations:

• Antibody Selection: The choice of antibody (whole IgG vs. fragments) affects pharmacokinetics, tumor penetration, and blood clearance, which in turn influence imaging timing and quality.

• Optimal Imaging Windows: Researchers should consider the time required for sufficient tumor accumulation versus background clearance when designing imaging protocols with radiolabeled antibodies.

• Quantification Approaches: Standardized uptake values (SUVs) or tumor-to-background ratios can be used to quantify CDCP1 expression levels from imaging data.

• Correlation with Expression: Imaging signal intensity should be validated against ex vivo CDCP1 expression analysis to confirm specificity and establish thresholds for detection.

These imaging approaches not only provide a means for non-invasive detection of CDCP1-expressing tumors but may also serve as companion diagnostics to identify patients most likely to benefit from CDCP1-targeted therapies.

What is known about the signaling mechanisms of CDCP1 and how do antibodies modulate these pathways?

Understanding CDCP1 signaling mechanisms and their modulation by antibodies is essential for developing effective targeted therapies:

CDCP1 Signaling Pathways:

• Src Family Kinase (SFK) Activation: CDCP1 interacts with and activates SFKs, particularly through phosphorylation at tyrosine residues including Tyr 734 .

• Downstream Effectors: Activated CDCP1 influences multiple downstream pathways involved in cell adhesion, migration, survival, and proliferation.

• Proteolytic Processing: CDCP1 can undergo proteolytic cleavage at sites 368Arg and 369Lys, generating a 70 kDa C-terminal fragment (CDCP1-CTF) that may have distinct signaling properties compared to the 135 kDa full-length protein (CDCP1-FL) .

Antibody-Mediated Modulation:

• Signaling Induction: Anti-CDCP1 antibodies like ch10D7 and 10D7 can initially induce CDCP1 signaling, as evidenced by increased phosphorylation of CDCP1-Y734 and Src-Y416 within 15-30 minutes of treatment .

• Signal Attenuation: Following initial activation, extended exposure to these antibodies leads to reduction in phosphorylated CDCP1-Y734 and Src-Y416 by 3 hours, with complete loss by 8 hours .

• Receptor Degradation: Prolonged antibody treatment (24-48 hours) results in significant reduction and eventual complete loss of CDCP1 expression, consistent with antibody-induced receptor degradation .

• Reversibility: After antibody withdrawal, CDCP1 re-expression begins within 24 hours and returns to control levels by 48 hours post-withdrawal .

Cell-Type Specificity:

• The impact of anti-CDCP1 antibodies on receptor levels varies across cancer types, with studies demonstrating antibody-induced CDCP1 loss in multiple cell lines from kidney, prostate, lung, colorectal, pancreatic, and ovarian cancers .

• This effect occurs regardless of whether cells express only CDCP1-FL, a mixture of CDCP1-FL and CDCP1-CTF, or only CDCP1-CTF .

The ability of anti-CDCP1 antibodies to modulate receptor signaling and induce receptor degradation has significant implications for therapeutic approaches. These mechanisms contribute to the anti-cancer effects of naked antibodies and provide rationale for developing antibody-drug conjugates that can deliver cytotoxic payloads following receptor-mediated internalization.

What methods are optimal for evaluating CDCP1 antibody specificity and binding characteristics?

Rigorous evaluation of CDCP1 antibody specificity and binding characteristics is crucial for research applications and therapeutic development:

Surface Plasmon Resonance (SPR) Spectroscopy:

• SPR represents the gold standard for determining antibody binding kinetics and affinity. Studies with ch10D7 and 10D7 antibodies used SPR to measure association (ka) and dissociation (kd) rates to calculate binding affinity (KD) to recombinant CDCP1 extracellular domain (CDCP1-ECD) .

• This technique provides quantitative measurements of antibody-antigen interactions in real-time without labeling, offering insights into both the strength and stability of binding.

Flow Cytometry-Based Assessment:

• Competitive Binding Assays: These assays evaluate specificity by determining if unlabeled competing antibodies can block the binding of fluorescently labeled antibodies to CDCP1-expressing cells. For example, studies showed that ch10D7-550 and 10D7-550 were unable to bind to CDCP1-expressing cells when binding sites were saturated with 10-fold excess of unlabeled competing antibody .

• Quantitative Analysis: Flow cytometry can determine the number of antibodies bound per cell, which has been shown to correlate with sensitivity to anti-CDCP1 ADCs. Studies have established approximately 5×10⁴ anti-CDCP1 antibodies bound per cell as a threshold for predicting anti-CDCP1 ADC efficacy .

Immunoprecipitation and Western Blotting:

• These techniques confirm antibody specificity by demonstrating selective pull-down and detection of CDCP1 protein.

• Western blotting can differentiate between antibodies that recognize full-length CDCP1-FL (135 kDa), the C-terminal fragment CDCP1-CTF (70 kDa), or both forms .

Immunohistochemistry and Immunofluorescence:

• These methods evaluate antibody specificity in tissue sections and cellular localization.

• Controls should include CDCP1-negative tissues/cells and competitive blocking with recombinant CDCP1 protein.

Epitope Mapping:

• Techniques such as hydrogen-deuterium exchange mass spectrometry (HDX-MS), X-ray crystallography, or binding to truncated/mutated CDCP1 constructs can identify the specific regions or amino acids recognized by the antibody.

• Understanding the epitope is particularly important as it may influence antibody function, including receptor internalization and signaling modulation.

When evaluating CDCP1 antibodies, researchers should employ multiple complementary methods to comprehensively characterize specificity and binding, as each technique provides different aspects of antibody-antigen interactions.

What are the key considerations for designing CDCP1 antibody-drug conjugate efficacy studies?

Designing robust efficacy studies for CDCP1 antibody-drug conjugates (ADCs) requires careful consideration of several key factors:

Model Selection:

• Cell Line Diversity: Include multiple cell lines with varying CDCP1 expression levels to establish correlations between expression and efficacy. Studies have shown that cell lines with fewer than 5×10⁴ anti-CDCP1 antibodies bound per cell are largely unresponsive to ch10D7-MMAE, suggesting this as a lower limit to predict anti-CDCP1 ADC efficacy .

• Patient-Derived Xenografts (PDXs): These models better represent tumor heterogeneity and have been successfully used to evaluate anti-CDCP1 ADCs. In combination with HER2-targeting ADC T-DM1, CDCP1-targeting ADCs demonstrated marked reduction in tumor burden of CDCP1+/HER2+ xenografts compared to either agent alone .

• Metastatic Models: Since CDCP1 expression increases in metastatic lesions of some cancers, metastatic models provide valuable insights into ADC efficacy against advanced disease .

Efficacy Parameters:

• In Vitro Assessment:

  • Determine IC50 values across multiple cell lines

  • Evaluate mechanism of cell death (apoptosis vs. other pathways)

  • Assess impact on cell cycle and proliferation

• In Vivo Assessment:

  • Tumor growth inhibition

  • Survival advantage compared to standard chemotherapy

  • Biomarker modulation (e.g., phosphorylated CDCP1 and SFK levels)

  • Impact on metastatic burden

Control and Comparison Arms:

• Include appropriate controls such as:

  • Naked antibody (without toxin conjugation)

  • Non-targeting ADC with the same linker-payload

  • Standard chemotherapy agents

  • Other targeted therapies relevant to the cancer type

• Combination studies:

  • For HER2+ cancers, combination with T-DM1 has shown superior efficacy compared to either agent alone

  • Other potential combinations should be explored based on cancer type and molecular characteristics

Pharmacokinetic/Pharmacodynamic (PK/PD) Considerations:

• Evaluate ADC stability and payload release kinetics

• Assess tumor penetration and accumulation using imaging techniques

• Determine optimal dosing schedule based on PK/PD relationships

• Monitor CDCP1 receptor dynamics, as studies show that antibody exposure leads to receptor degradation within 24-48 hours, with re-expression occurring after antibody withdrawal

Toxicity Assessment:

• Evaluate on-target/off-tumor effects based on CDCP1 expression in normal tissues

• Assess toxicities related to the payload mechanism

• Determine maximum tolerated dose (MTD) and therapeutic window

By addressing these key considerations, researchers can design comprehensive efficacy studies that not only evaluate the potential of CDCP1-targeted ADCs but also inform future clinical development strategies.

How can researchers troubleshoot variability in CDCP1 antibody performance across different experimental systems?

Variability in CDCP1 antibody performance across experimental systems is a common challenge that requires systematic troubleshooting approaches:

Antibody Characterization and Quality Control:

• Batch-to-Batch Variation: Establish quality control protocols to ensure consistent antibody production and performance, including affinity testing via SPR and functional assays.

• Storage and Handling: Improper storage can lead to antibody degradation and reduced activity. Follow manufacturer recommendations for temperature, buffer conditions, and avoid repeated freeze-thaw cycles.

• Antibody Format: Consider whether the native antibody or various conjugated forms (HRP, FITC, PE, Alexa Fluor conjugates) are appropriate for specific applications. Santa Cruz Biotechnology's CDCP1 Antibody (D-1) is available in multiple formats that may perform differently across experimental systems .

CDCP1 Expression and Processing Variability:

• Full-Length vs. Cleaved Forms: Some cell lines express only full-length CDCP1-FL (135 kDa), others express a mixture of CDCP1-FL and CDCP1-CTF (70 kDa), and some express only CDCP1-CTF . Ensure your antibody recognizes the appropriate form(s) present in your experimental system.

• Expression Level Quantification: Use flow cytometry to quantify cell surface CDCP1 levels, as this has been shown to correlate with sensitivity to anti-CDCP1 ADCs. Cell lines with fewer than 5×10⁴ anti-CDCP1 antibodies bound per cell may show minimal response .

• Dynamic Regulation: CDCP1 expression can be dynamically regulated. Following antibody treatment, CDCP1 levels can decrease significantly within 24-48 hours but return to baseline 48 hours after antibody withdrawal . Consider these dynamics when designing experiments.

Experimental System Optimization:

• Fixation and Permeabilization: For immunohistochemistry and immunofluorescence, optimize fixation conditions as over-fixation can mask epitopes while under-fixation may compromise tissue morphology.

• Antigen Retrieval: Different tissues may require specific antigen retrieval methods. Systematically test heat-induced epitope retrieval (HIER) with various buffers (citrate, EDTA, Tris) and pH conditions.

• Blocking Conditions: Optimize blocking buffers to minimize non-specific binding, which can vary across tissue types and cell lines.

• Detection Systems: When transitioning between detection methods (e.g., from Western blot to IHC), optimize secondary antibodies and detection reagents for each system.

Controls for Troubleshooting:

• Positive and Negative Controls: Include cell lines or tissues with known high or absent CDCP1 expression to validate antibody performance in each experiment.

• Knockdown/Knockout Validation: CDCP1 knockdown or knockout samples provide definitive controls for antibody specificity.

• Competing Peptide Controls: Pre-incubation of the antibody with recombinant CDCP1 protein or peptide should abolish specific staining.

• Alternative Antibodies: When possible, confirm results using antibodies targeting different CDCP1 epitopes.

By systematically addressing these factors, researchers can identify sources of variability and develop standardized protocols that ensure consistent CDCP1 antibody performance across different experimental systems.

What emerging applications exist for CDCP1 antibodies in combination therapies?

CDCP1 antibodies show significant potential in combination therapeutic approaches, with several emerging applications based on recent preclinical findings:

Combination with HER2-Targeted Therapies:

• The combination of CDCP1-targeting ADC (ch10D7-MMAE) with HER2-targeting ADC T-DM1 has demonstrated superior efficacy in CDCP1+/HER2+ cancer models compared to either agent alone .

• In preclinical studies, this combination markedly reduced tumor burden of CDCP1+/HER2+ xenografts and prolonged mouse survival compared with T-DM1 or ch10D7-MMAE monotherapy .

• This synergy is particularly relevant for HER2+ breast cancers, where approximately 80% of tumors also express CDCP1, providing a large potential patient population for this combination approach .

Rational Combinations Based on Signaling Pathway Interactions:

• Since CDCP1 signaling involves Src family kinases, combinations with Src inhibitors might provide synergistic effects by simultaneously targeting the receptor and its downstream effectors.

• The involvement of CDCP1 in cell adhesion and migration suggests potential combinations with other therapies targeting the tumor microenvironment or metastatic processes.

Multi-Modal Approaches Combining Imaging and Therapy:

• The demonstrated utility of 89Zr-labeled anti-CDCP1 antibodies for imaging suggests theranostic applications where the same antibody can be used for both diagnosis and treatment .

• Such approaches could involve initial imaging with 89Zr-labeled antibodies to identify patients with CDCP1-expressing tumors, followed by treatment with the same antibody conjugated to cytotoxic payloads.

• Radio-ligand therapy using 177Lu-labeled anti-CDCP1 antibodies has shown efficacy in prostate cancer xenografts and could be combined with other treatment modalities .

Strategies to Address Resistance Mechanisms:

• Given that prolonged antibody exposure leads to CDCP1 degradation followed by re-expression after antibody withdrawal , pulsed or cyclical treatment regimens might be more effective than continuous exposure.

• Combination with agents that prevent receptor re-expression or that target alternative pathways activated during periods of CDCP1 downregulation could enhance therapeutic efficacy.

Immunotherapy Combinations:

• Anti-CDCP1 ADCs might synergize with immune checkpoint inhibitors by enhancing tumor antigen release and immunogenic cell death.

• The potential immunomodulatory effects of CDCP1 targeting merit investigation in combination with various immunotherapeutic approaches.

As these combination strategies move toward clinical development, careful consideration of dosing schedules, sequence of administration, and potential overlapping toxicities will be essential to maximize therapeutic benefit while minimizing adverse effects.

How might patient selection strategies evolve for CDCP1-targeted therapies?

Patient selection strategies for CDCP1-targeted therapies are likely to evolve in several sophisticated directions as our understanding of CDCP1 biology and clinical data accumulate:

Multi-Parameter Expression Analysis:

• Beyond Simple Expression Levels: Future approaches will likely move beyond binary assessment of CDCP1 expression (positive/negative) to more nuanced quantitative evaluation. Studies have already established that approximately 5×10⁴ anti-CDCP1 antibodies bound per cell represents a threshold for predicting anti-CDCP1 ADC efficacy .

• Form-Specific Assessment: Distinguishing between full-length CDCP1-FL (135 kDa) and the C-terminal fragment CDCP1-CTF (70 kDa) may become important, as some cell lines express only one form while others express both . The therapeutic implications of these different forms require further investigation.

• Phosphorylation Status: Since phosphorylation at specific tyrosine residues (e.g., Tyr 734) enhances CDCP1 signaling capabilities , assessing phosphorylation status might provide additional stratification criteria.

Imaging-Based Selection:

• PET-CT imaging with 89Zr-labeled anti-CDCP1 antibodies has demonstrated effectiveness for detecting CDCP1-expressing tumors in preclinical models . This approach could evolve into a clinical companion diagnostic to identify patients most likely to benefit from CDCP1-targeted therapies.

• Quantitative imaging parameters, such as standardized uptake values (SUVs), could potentially establish thresholds for predicting response to therapy.

• Whole-body imaging would also address the issue of heterogeneous CDCP1 expression between primary tumors and metastatic lesions, as observed in ER+/HER2- breast cancer where expression increases from 44.9% in primary tumors to 74.3% in distant metastases .

Integrated Biomarker Approaches:

• Combining CDCP1 assessment with other molecular markers could enhance patient selection. For example, in HER2+ breast cancers, dual assessment of HER2 and CDCP1 could identify patients suitable for combination therapy with T-DM1 and anti-CDCP1 ADCs .

• Genomic or transcriptomic signatures associated with CDCP1 dependence might emerge as additional selection tools.

• Liquid biopsy approaches detecting circulating CDCP1 or CDCP1-expressing circulating tumor cells could provide less invasive means of patient selection and monitoring.

Adaptive Selection Strategies:

• Given that CDCP1 expression can be dynamically regulated, with re-expression occurring after antibody withdrawal , sequential biopsies or imaging might be necessary to guide treatment schedules.

• Changes in CDCP1 expression or signaling during disease progression or after prior therapies might identify new windows of opportunity for CDCP1-targeted interventions.

As CDCP1-targeted therapies advance through clinical development, these selection strategies will likely be refined based on correlations between biomarker data and clinical outcomes, ultimately leading to more personalized treatment approaches for cancer patients.